Bioequivalence Study of Primidone Tablets 50 mg of Dr. Reddy's Under Fasting Conditions

NCT ID: NCT01132040

Last Updated: 2010-05-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-08-31
• Study Completion Date: 2006-09-30

Brief Summary

The purpose of this study is to assess the bioavailability of Primidone 50 mg tablets of Dr.Reddy's comparing with that of Mysoline@ tablets of Yamanouchi Pharma Technologies Inc, in healthy, adult, human subjects under fasting conditions.

Detailed Description

An open label, balanced. randomized, two-treatment, two-period, two-sequence, single dose,crossover, bioequivalence study of Primidone 50 mg tablets of Dr.Reddy's Laboratories Limited, Generics, India comparing with that of Mysoline (containing Primidone 50 mg) tablets of Yamanouchi Pharma Technologies Inc, Norman, OK in healthy, adult, human subjects under fasting conditions with a washout period of 14 days.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Primidone

Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories

Group Type: EXPERIMENTAL

Primidone

Intervention Type: DRUG

Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories Limited

Mysoline

Mysoline Tablets of Yamanouchi Pharma Technologies Inc,

Group Type: ACTIVE_COMPARATOR

Primidone

Intervention Type: DRUG

Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories Limited

Interventions

Primidone

Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories Limited

Intervention Type: DRUG

Other Intervention Names

Mysoline

Eligibility Criteria

Inclusion Criteria

Subjects must fulfill all of the following criteria to be considered for inclusion into this study:

1. Subjects who will provide written informed consent.

2. Subjects must be healthy, adult, human beings within 18-45 years of age (both inclusive)weighing at least 50 kg.

3. Having a Body Mass Index (BMI) between 18.5 and 24.9 (both inclusive), calculated as weight in Kg/height in m2

4. Subjects must be of normal health as determined by medical history and physical examination performed within 21 days prior to the commencement of the study.

5. Subjects whose screening laboratory values are within normal limits or considered by the physician/investigator to be of no clinical significance.

6. Availability of the subject for the entire study period and willingness to adhere to the protocol requirements as evidenced by written informed consent.

Exclusion Criteria

The subjects will be excluded based on the following criteria during screening and during the study

1. Subjects incapable of understanding the informed consent.

2. Subjects who have:

1. Systolic blood pressure less than 90 mm ofHg or more than 140 mm of Hg

2. Diastolic blood pressure less than 60 mm of Hg or more than 94 mm of Hg. Minor deviations (2-4 mm of Hg) at check-in may be acceptable at the discretion of the physician/investigator.

3. Pulse rate below 50/min or above 100/min.

3. History of hypersensitivity or idiosyncratic reaction to study drug or any other related drugs.

4. Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function.

5. Consumption of grapefruit for the past ten days prior to the dosing day until the completion of the study.

6. Regular smoker who has a habit of smoking more than nine cigarettes per day and has difficulty in abstaining from smoking from 48 hours before dosing and during sampling period.

7. Subjects who have taken over the counter or prescribed medications and enzyme modifying or any systemic medication for during the last 7 and 30 days respectively before dosing.

8. Subjects who have participated in any other clinical investigation using experimental drug/donated blood in past 90 days before the date of start of study.

9. Subjects with clinically significant abnormalities (such as Laboratory Findings, ECG, X-Ray,Drugs of abuse, Alcohol etc.,) and/or with significant diseases (such as HIV, Hey, Syphilis,Hepatitis B etc.,).

10. Female subjects who are pregnant or who are able (women with child bearing potential) to become pregnant during the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Dr. Reddy's Laboratories Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Dr. Reddy's Laboratories Limited

Principal Investigators

Mohanlal shiva prasad sayana

Role: PRINCIPAL_INVESTIGATOR

Bioserve Clinical Research Pvt. Ltd., Hyderabad, A.P.

Locations

Bioserve Clinical Research Pvt. Ltd,

HYD, Andhra Pradesh, India

Countries

India

Other Identifiers

P-620/06

Identifier Type: -

Identifier Source: org_study_id